Genevieve Kanter

Biography

Genevieve P. Kanter, PhD, is Associate Professor of Public Policy at the USC Price School of Public Policy.

She is an economist whose research focuses on the economics of regulatory institutions, primarily in health care, with a focus on good governance, conflicts of interest, and government decision-making. Her research has examined conflicts of interest in medicine, FDA advisory committees, the revolving door at regulatory agencies, and transparency policies.

Professor Kanter’s research and essays have been published in leading academic journals, including JAMA, the New England Journal of Medicine, Health Affairs, and Milbank Quarterly, and her work and expert commentary have been featured in major media outlets, including the New York Times, Washington Post, Wall Street Journal, Reuters, AP, NPR, CNBC, Politico, the Atlantic, and STAT.

She serves on the Medicare Evidence Development and Coverage Advisory Committee (the federal advisory committee providing guidance on Medicare coverage of medical products) and is on the editorial board of BMC Medical Ethics. She is former Chair of the Advisory Board of the AcademyHealth Health Economics Interest Group.

Professor Kanter received a PhD in Economics and in Sociology from the University of Chicago; completed an NIH postdoctoral fellowship in health and demography at Princeton University; and completed research fellowships in health policy and ethics at Massachusetts General Hospital and Harvard University.

Selected Publications

• Kanter G.P., Mankowitz T. (2026). Prevalence of ties to industry-funded organizations among patient and consumer representatives on FDA advisory committees. Health Affairs Schol 2026; qxag296
• Kanter, G.P. (2026). Prediction markets in clinical trials and drug approval. JAMA Health Forum, 7:e262953.
• Kanter, G. P. (2026). Conflicts of interest in advisory committees – facts, fallacies, and the limits of reform. New England Journal of Medicine, 394:1150-1152.
• Kanter, G. P., Mankowitz, T., & Lurie, P. (2025). Conflicts of interest in federal vaccine advisory committees. JAMA, 334:1295-1297.